Examining Use of Extended Radiation Therapy for Metastatic Cancer Near End of Life

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JANUARY 14, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2021.4468?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=011422

About JAMA Health Forum: JAMA Health Forum has transitioned from an information channel to an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

What The Study Did: This study investigated how common the use of extended radiation therapy is to treat metastatic cancer in patients near the end of life despite guidelines advising against this use.

Authors: Erin F. Gillespie, M.D., of Memorial Sloan Kettering Cancer Center in New York, is the corresponding author.

 

(doi:10.1001/jamahealthforum.2021.4468)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.